Indexed keywords
AMINOTRANSFERASE;
FOSINOPRIL;
LEFLUNOMIDE;
ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD;
ADULT;
ALOPECIA;
AMINOTRANSFERASE BLOOD LEVEL;
ARTICLE;
CLINICAL STUDY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COUGHING;
DIARRHEA;
DRUG EFFICACY;
FEMALE;
HUMAN;
IMMUNOGLOBULIN A NEPHROPATHY;
MAJOR CLINICAL STUDY;
MALE;
PRIORITY JOURNAL;
PROTEINURIA;
RANDOMIZED CONTROLLED TRIAL;
REMISSION;
UNSPECIFIED SIDE EFFECT;
ADJUVANTS, IMMUNOLOGIC;
ADOLESCENT;
ADULT;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
FEMALE;
FOSINOPRIL;
GLOMERULAR FILTRATION RATE;
GLOMERULONEPHRITIS, IGA;
HUMANS;
ISOXAZOLES;
MALE;
MIDDLE AGED;
1
0023893178
IgA nephropathy the most common glomerulonephritis worldwide. a neglected disease in the united states?
Julian BA Waldo FB Rifai A et al. IgA nephropathy the most common glomerulonephritis worldwide. A neglected disease in the united states? Am. J. Med. 1988 84 129 30.
(1988)
Am. J. Med. , vol.84
, pp. 129-30
Julian, B.A.1
Waldo, F.B.2
Rifai, A.3
2
33645867794
Regulation of B cell function by the immunosuppressive agent leflunomide
Siemasko KF Chong AS. Regulation of B cell function by the immunosuppressive agent leflunomide. Clin. Exp. Immunol. 1999 115 221 8.
(1999)
Clin. Exp. Immunol. , vol.115
, pp. 221-8
Siemasko, K.F.1
Chong, A.S.2
3
0029052321
Inhibition of protein tyrosine phosphorylation T cells by a novel immunosuppressive agent, leflunomide
Xu XL Williams JJ Bremer EG et al. Inhibition of protein tyrosine phosphorylation T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 1995 270 12398 403.
(1995)
J. Biol. Chem. , vol.270
, pp. 12398-403
Xu, X.L.1
Williams, J.J.2
Bremer, E.G.3
4
0036819728
Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction
Hardinger KL Wang CD Schnitzler MA et al. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am. J. Transplant. 2002 2 867 71.
(2002)
Am. J. Transplant. , vol.2
, pp. 867-71
Hardinger, K.L.1
Wang, C.D.2
Schnitzler, M.A.3
6
0033383526
Leflunomide: A review of its use in active rheumatoid arthritis
Amitabyh P. Leflunomide: A review of its use in active rheumatoid arthritis. Drugs 1999 58 1137 64.
(1999)
Drugs , vol.58
, pp. 1137-64
Amitabyh, P.1
7
0029618768
Inhibition of smooth muscle cell proliferation in vitro by leflunomide
Nair RV Cao W. Inhibition of smooth muscle cell proliferation in vitro by leflunomide. Immunol. Lett. 1995 48 77 80.
(1995)
Immunol. Lett. , vol.48
, pp. 77-80
Nair, R.V.1
Cao, W.2
8
0034925128
Benefits of leflunomide in systemic lupus erythematosus
Remer CF Weisman MH Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus. Lupus 2001 10 480 83.
(2001)
Lupus , vol.10
, pp. 480-83
Remer, C.F.1
Weisman, M.H.2
Wallace, D.J.3
9
33645847367
Clinical trials of leflunomide in treatment lupus nephritis
Zhang FS Zhao YH Sun Y et al. Clinical trials of leflunomide in treatment lupus nephritis. Chin. J. Rheum. Arth. 2002 6 282 4.
(2002)
Chin. J. Rheum. Arth. , vol.6
, pp. 282-4
Zhang, F.S.1
Zhao, Y.H.2
Sun, Y.3
10
33645846747
27 cases of leflunomide in treatment of refractory syndrome
Yu RJ Wu XF Zhao HA et al. 27 cases of leflunomide in treatment of refractory syndrome. Chongqing Med. 2003 32 694 5.
(2003)
Chongqing Med. , vol.32
, pp. 694-5
Yu, R.J.1
Wu, X.F.2
Zhao, H.A.3
13
0033142080
Management of IgA nephropathy: Evidence-based recommendations
Nolin L. Management of IgA nephropathy: Evidence-based recommendations. Kidney Int. 1999 70 s56.
(1999)
Kidney Int. , vol.70
, pp. 56
Nolin, L.1
14
0002314280
ACE inhibitor for IgA nephropathy: A meta analysis
Dallin JJ. ACE inhibitor for IgA nephropathy: A meta analysis. J. Am. Soc. Nephrol. 1998 9 86A.
(1998)
J. Am. Soc. Nephrol. , vol.9
Dallin, J.J.1
